Shockwave Medical, Inc., now part of Johnson & Johnson MedTech and a global leader in circulatory restoration, announced today that it will showcase data from 23 company-sponsored studies—including three late-breaking presentations—at EuroPCR 2025, taking place from May 20–23 in Paris.
These studies will spotlight data from Shockwave’s advanced cardiovascular portfolio, featuring its market-leading Intravascular Lithotripsy (IVL) platform and innovative Reducer technology, both designed to redefine treatment standards for cardiovascular disease.
“The depth and diversity of research being presented at EuroPCR reflect our ongoing mission to meet the urgent needs of cardiovascular patients,” said Nick West, M.D., Chief Medical Officer at Shockwave Medical. “Our pioneering work in IVL and coronary sinus reduction is enabling physicians to achieve better patient outcomes and pushing the boundaries of what’s possible in cardiovascular care.”
Key Late-Breaking Presentations
- EMPOWER CAD Study
Room 242AB | May 20, 3:00–4:00 p.m. CEST | Presenter: Margaret McEntegart, M.D., Columbia University Medical Center
A landmark, all-female, multi-center study evaluating IVL treatment for calcified lesions in women with coronary artery disease, representing real-world, post-market insights. - BALI Trial – Balloon Angioplasty vs. Lithotripsy
Room 242AB | May 20, 3:00–4:00 p.m. CEST | Presenter: Andreas Torp Kristensen, M.D., Arhus University Hospital
A randomized multicenter trial comparing outcomes between conventional lesion preparation and routine lithotripsy in treating calcified coronary lesions. - RollerCoastr-EPIC22 Trial
Room 242AB | May 20, 3:00–4:00 p.m. CEST | Presenter: Alfonso Jurado, M.D., Ph.D., La Paz University Hospital
A head-to-head, randomized study comparing rotational atherectomy, excimer laser, and IVL in patients with calcified coronary stenosis over a one-year period.
Poster Presentation
- ANOCA Study – Coronary Sinus Reducer in Non-Obstructive CAD
May 22, 11:29 a.m. CEST | Presenter: Ranil de Silva, M.D., Imperial College London
Focuses on the application of the Shockwave Reducer in patients with refractory angina and non-obstructive coronary artery disease.
Symposia & Educational Highlights
May 21 – Sponsored Symposium
“Treat Calcium Right the First Time”
Room 242AB | 12:30–2:00 p.m. CEST
A case-based discussion on IVL as a first-line treatment for coronary artery calcification.
Moderator: Emanuele Barbato, M.D.
Panelists:
Angela McInerney, M.D. • Margaret McEntegart, M.D. • Niels Tuhe Olsen • Marco Pavani, M.D. • Simon Wilson, M.D.
May 22 – Sponsored Symposium
“Road to Relief: Refractory Angina and the Shockwave Reducer”
Room 251 | 12:30–1:30 p.m. CEST
An in-depth panel on the real-world burden of refractory angina and Reducer treatment outcomes.
Moderator: James Spratt, M.D.
Panelists:
Ranil de Silva, M.D. • Mariusz Tomaniak, M.D., Ph.D. • Felix Woitek, M.D. • Tommaso Gori, M.D., Ph.D.
Scientific Sessions Featuring Shockwave Technologies
Tuesday, May 20
- 1:15–2:15 p.m.: Coronary Sinus Reducer Implantation – Kevin Cheng
Wednesday, May 21
- 8:30–9:30 a.m.: Optimizing Calcium Treatment – Breda Hennessey, Yongcheol Kim
- 8:30–9:30 a.m.: Calcified Nodules – Emanuele Barbato
- 9:45–10:45 a.m.: UK Coronary Sinus Reducer Audit – Kevin Cheng
- 9:45–10:45 a.m.: IVL for Left Main Disease – Ankush Gupta
- 11:15–12:15 p.m.: GISE Shockcalcium Registry – Guilia Nardi
- 3:00–4:00 p.m.: Refractory Angina in CMD – Szymon Wlodarczak
Thursday, May 22
- 8:30–9:30 a.m.: Atherectomy vs. IVL – Pedro Lemos, Sheeran Al Shaikh
- 11:15–12:15 p.m.: REDUCER I (ANOCA) – Ranil de Silva
- 1:45–2:45 p.m.: FRANCE-LILI Registry – Guillaume Cayla
- 3:00–4:00 p.m.: CS Reducer in CMD – Szymon Wlodarczak
- 3:00–4:00 p.m.: 12-month Clinical Outcomes – Szymon Wlodarczak
- 4:15–5:15 p.m.: IVL Prior to DCB Angioplasty – Franz Kleber
Hands-On Training and Experience
Attendees are invited to participate in three days of immersive training sessions at the Shockwave Training Village. Highlights include:
- Virtual reality experiences with IVL
- Hands-on simulators
- Best practice presentations
Visit Shockwave Medical at Booth F19 and register for sessions at the EuroPCR 2025 microsite to explore how Shockwave’s technology is transforming cardiovascular care.
About Shockwave Medical
Shockwave Medical Inc., part of Johnson & Johnson MedTech, is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Its Reducer technology, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom, is designed to provide relief to the millions of patients worldwide suffering from refractory angina by redistributing blood flow within the heart. Learn more at www.shockwavemedical.com.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation, we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. Shockwave Medical, Inc. is part of Johnson & Johnson MedTech.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.as a result of new information or future events or developments.
